Scientists at the Massachusetts Institute of Technology (MIT) have developed a new nanodevice to block the gene that confers drug resistance and deliver a sustained release of drugs.
According to the 2015 Sleep in America Poll, stress and poor health are key factors in shorter sleep durations and worse sleep quality.
In a new survey, nearly 75 percent of physicians believe that state prescription drug monitoring programs have led to a reduction in the prescribing of opioids.
The Food and Drug Administration (FDA) announced that prescription testosterone product labels must be changed to clarify the approved use of these medications and information on the possible increased risk of heart attacks and strokes in patients taking testosterone must also be added.
Biodegradable nano drones that deliver a specific healing molecule to fat deposits in arteries may help in preventing heart attacks due to atherosclerosis.
A new report predicts that the prevalence of chronic kidney disease (CKD) in adults aged 30 and over will rise from the current rate of 13.2 percent to 16.7 percent by 2030.
The Food and Drug Administration (FDA) has issued a warning to not buy or use Elimulating Weight & Toxin Keeping Beauty, a product promoted for weight loss.
Amgen announced the launch of Neulasta (pegfilgrastim) Delivery Kit that allows the healthcare provider to initiate Neulasta on the same day as chemotherapy along with a full dose of Neulasta the following day.
The Food and Drug Administration (FDA) is warning consumers to not use or buy SEx Men, Super Hard, Santi Scalper, Vigra, Plant Vigra, Vigour 300, MME MAXMAN, Hard Wang, FX3000 after they were found to contain hidden drug ingredients.
The Food and Drug Administration (FDA) has accepted for filing and review the supplemental Biologics License Application (sBLA) for Yervoy (ipilimumab; Bristol-Myers Squibb) for the adjuvant treatment of patients with stage 3 melanoma who are at high risk of recurrence following complete surgical resection.
More antibiotic prescriptions per person are written in wealthy areas of the United States as a result of competition among physicians and retail clinics, a team of researchers has found.
Nut consumption is associated with reduced total mortality risk and death due to cardiovascular disease, particularly ischemic heart disease, across different ethnic groups and people of low SES
Researchers from the University of Buffalo have found a way to improve remyelination for myelin-based diseases like multiple sclerosis (MS).
The FDA has accepted for filing the New Drug Application (NDA) for Xadago (safinamide; Newron and Zambon) as add-on therapy in both early and mid-to-late stage Parkinson's disease (PD) patients who are inadequately managed on their current treatment.
An analysis by the United States Government Accountability Office (GAO) has found that about 1/3 of older adults with dementia who resided >100 days in a nursing home in 2012 were prescribed an antipsychotic.
Many of the tests performed to screen for chronic kidney disease (CKD) may offer little clinical benefit on diagnosis and management, according to a research letter.
Ipsen, in collaboration with the FDA is releasing a third batch of Increlex (mecasermin [rDNA origin]), since the initial resumption of product supply in May 2014.
The Food and Drug Administration (FDA) has warned against the use of Libigrow XXX Treme, Night Man, Black King Kong, 72HP, Tibet Babao, and Germany Niubian supplements promoted for sexual enhancement.
The FDA has warned consumers to not buy or use the weight loss supplements Oxy ELITE Pro Super Thermogenic, Nine Slim, Seven Slim, and Botanical Slimming (Red) after they were found to contain undeclared drug ingredients.
The FDA has issued a Complete Response Letter (CRL) for the supplemental New Drug Application (sNDA) for the use of Exparel (bupivacaine liposome injectable suspension) in nerve block to provide postsurgical analgesia.
The FDA has accepted for Priority Review the Biologics License Application (BLA) for asfotase alfa in the treatment of patients with infantile-and juvenile-onset hypophosphatasia (HPP).
Shire has submitted a New Drug Application (NDA) to the FDA for lifitegrast for the treatment of signs and symptoms of dry eye disease in adults.
Boehringer Ingelheim announced that it has submitted a Biologics License Application (BLA) to the FDA, requesting accelerated approval for the use of idarucizumab to reverse the anticoagulant effect of Pradaxa (dabigatran etexilate mesylate).
A new study suggests that many patients with COPD may be undertreated (particularly with long-acting maintenance medications), despite recommended treatment guidelines.
Gilead Sciences announced results from ION-4, a Phase 3 study evaluating Harvoni (ledipasvir 90mg/sofosbuvir 400mg) for the treatment of genotypes 1 or 4 chronic hepatitis C virus (HCV) infection among patients co-infected with HIV.
Bristol-Myers Squibb Company announced results from ALLY-2, a Phase 3 trial evaluating the use of daclatasvir and sofosbuvir for the treatment of patients with chronic hepatitis C virus (HCV) co-infected with HIV.
The Centers for Disease Control and Prevention's (CDC) Advisory Committee on Immunization Practices (ACIP) has issued new recommendations on immunizations, including influenza, serogroup B meningococcal, and human papillomavirus (HPV) vaccination.
The Food and Drug Administration (FDA) has approved Liletta (levonorgestrol-releasing intrauterine system; Actavis and Medicines360) for use by women to prevent pregnancy for up to three years.
Corgenix Medical Corporation announced that it has received emergency use authorization (EUA) from the Food and Drug Administration (FDA) for its ReEBOV Antigen Rapid Test for use in patients with signs and symptoms of Ebola Zaire virus infection in conjunction with epidemiological risk factors, including geographic locations with high prevalence of Ebola infection.
Sanofi announced that the Food and Drug Administration (FDA) has approved once-daily Toujeo (insulin glargine [rDNA origin]) injection 300 U/mL to improve glycemic control in adults with type 1 and type 2 diabetes.
The Food and Drug Administration (FDA) announced that multi-dose diabetes pen devices intended for single patient use only are now required to add additional label warnings prohibiting the sharing of these injectable medicines.
Research published in The Journal of Biological Chemistry suggests that a newly designed molecule, if developed into a drug, could slow the progression of Parkinson's disease.
The Food and Drug Administration (FDA) has approved Avycaz (ceftazidime/avibactam; Actavis) for the treatment of adults with complicated intra-abdominal infections (cIAI) in combination with metronidazole and for patients with complicated urinary tract infections (cUTI) including pyelonephritis.
Researchers have created nelfinavir-like compounds that stopped Streptococcus pyogenes bacteria from producing the streptolysin S (SLS) toxin, an important virulence factor during infection.
The percentage of adults aged 20 years and older that used a prescription opioid analgesic in the past 30 days remained stable through 2011-2012, although use has doubled compared to 1988-1994, according to a new survey from the National Center for Health Statistics and the Centers for Disease Control and Prevention (CDC).
A skin test may help diagnose Alzheimer's and Parkinson's diseases by detecting potential biomarkers, new research has shown.
The Infectious Diseases Society of America (IDSA) has issued a list of five tests or treatments that physicians and patients should question.
Heritage Pharmaceuticals announced a voluntary nationwide recall of 10 lots of Colistimethate for Injection 150mg, and three lots of Rifampin for Injection 600mg.
GlaxoSmithKline announced that alli (orlistat) capsules have returned to most stores in the United States and Puerto Rico following the voluntary recall in March 2014.
Eisai announced results from a Phase 3 trial investigating the use of eribulin vs. dacarbazine in patients with advanced soft tissue sarcomas.
A pre-exposure prophylaxis (PrEP) regimen of tenofovir/emtricitabine taken before and after sex reduced the risk of HIV among men who have sex with men (MSM) by an average of 86 percent, according to results presented by a French national HIV research agency.
Pregnant women with various classes of obesity should not gain any weight until mid-pregnancy or later for optimal pregnancy outcomes, according to a new study in the journal Obesity.
The first genetic variation linked to increased risk and severity of peripheral neuropathy following treatment with a common chemotherapy drug has been identified, according to scientists at St. Jude Children's Research Hospital.
Nurture, not nature, may play a greater role in childhood obesity as researchers have found that environment may be an equal (if not stronger) force in determining obesity compared to the mother's diet.
The Federal Trade Commission (FTC) has announced that the agency is actively challenging several marketers of mobile apps promoted to detect symptoms of melanoma (even in its early stages) due to deceptive claims.
A new study shows that people who have aspirin resistance may be more likely to have more severe and larger strokes than those who are still responsive to aspirin.
Introducing peanut products into the diets of infants at high risk of developing peanut allergy was safe and led to an 81% reduction in the subsequent allergy development, reports a new study.
Sagent announced its voluntary nationwide recall of two lots of Atracurium Besylate Injection 50mg/5mL single-dose vials and four lots of Atracurium Besylate Injection 100mg/10mL multi-dose vials.
bioLytical Laboratories announced that the Food and Drug Administration (FDA) has approved its INSTI HIV Antibody Test for the detection of antibodies to HIV type 2 (HIV-2).
An investigational compound may help metabolize acetaldehyde for people with impaired ability to detoxify, a study supported by the National Institute on Alcohol Abuse and Alcoholism (NIAAA) has shown.
The Food and Drug Administration (FDA) has approved Farydak (panobinostat; Novartis) for the treatment of patients with multiple myeloma who have received at least two prior therapies, including bortezomib and an immunomodulator.
Meda announced that the Food and Drug Administration (FDA) has approved Dymista (azelastine HCl and fluticasone propionate) for the relief of symptoms of seasonal allergic rhinitis (SAR) in patients ages 6-11 who require treatment with both components.
Over 90 percent of new HIV infections in the United States could be prevented by diagnosing those living with HIV and providing prompt, ongoing care and treatment that includes the use of antiretroviral therapy (ART), according to new research from the Centers for Disease Control and Prevention (CDC) and published in JAMA Internal Medicine.
Eli Lilly and Company and Incyte announced results from a second Phase 3 trial with baricitinib in patients with rheumatoid arthritis.
The Food and Drug Administration (FDA) has accepted for Priority Review the Biologics License Application (BLA) for Kanuma (sebelipase alfa; Synageva BioPharma) for the treatment of lysosomal acid lipase deficiency (LAL Deficiency).
The Food and Drug Administration (FDA) has accepted for Priority Review a supplemental New Drug Application (sNDA) for Rapamune (sirolimus; Pfizer) for the treatment of lymphangioleiomyomatosis (LAM).
The Food and Drug Administration (FDA) has accepted Taiho's New Drug Application (NDA) for review for TAS-102 (nonproprietary names: trifluridine and tipiracil HCl) for the treatment of refractory metastatic colorectal cancer (mCRC).
Data from a Phase 2b trial showed that patients with peanut allergy using Viaskin Peanut (DBV Technologies) showed significant improvement using this epicutaneous immunotherapy (EPIT) after one year.
The Food and Drug Administration (FDA) has accepted the NDA for review for Belbuca (buprenorphine HCl; Endo and BioDelivery Sciences) buccal film for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate.
The Centers for Disease Control and Prevention (CDC) has reported the discovery of a new virus that may have contributed to the death of a resident in eastern Kansas in late spring of 2014.
The Food and Drug Administration (FDA) has approved Covidien's VenaSeal system for permanent treatment of varicose veins of the legs by sealing the affected superficial veins with an adhesive.
Compared to healthy individuals, women with multiple sclerosis (MS) may have lower levels of key antioxidant and anti-inflammatory nutrients such as folate and vitamin E.
Dipeptidyl peptidase-4 (DPP-4) inhibitors, commonly used to treat high blood glucose levels, have also shown efficacy against low blood sugar levels in a recent study.
A new study suggests that the use of statins may not lower the risk for Parkinson's disease.
Researchers at Albert Einstein College of Medicine of Yeshiva University have discovered a potential explanation as to why older mothers face a greater risk for having offspring born with conditions characterized by abnormal chromosome numbers, such as Down syndrome.
The Food and Drug Administration (FDA) has approved for marketing 23andMe's Bloom Syndrome carrier test to determine whether a healthy person expresses a gene variant that could lead to their child inheriting the disorder.
The U.S. Department of Health and Human Services (HHS) has announced that the 2015 Dietary Guidelines Advisory Committee (DGAC) has submitted recommendations to HHS Secretary Sylvia M. Burwell and Agriculture Secretary Tom Vilsack for the 2015 edition of the Dietary Guidelines for Americans.
Researchers believe it may be possible to reduce the development of opioid tolerance if the compound CXCL1 is neutralized or blocked in patients taking opioids for chronic management of severe pain.
Treatment with pimecrolimus for eczema was found unlikely to increase the risk of cancer in children, according to a post-marketing study.
The Food and Drug Administration (FDA) has issued recommendations for healthcare professionals regarding endoscopic retrograde cholangiopancreatography (ERCP) endoscopes (duodenoscopes) in response to adverse event reports of multidrug-resistant bacterial infections in patients who have undergone ERCP with reprocessed duodenoscopes, even when manufacturer reprocessing instructions are followed correctly.
Treatment with Eylea (aflibercept; Regeneron) led to greater average visual improvement than Avastin (bevacizumab; Genentech) or Lucentis (ranibizumab; Genentech) when vision was 20/50 or worse at treatment initiation, but similar improvement when the starting vision was 20/40-20/32, data from a clinical trial has shown.
The Food and Drug Administration (FDA) has accepted and granted Priority Review to the New Drug Application (NDA) for cobimetinib in combination with Zelboraf (vemurafenib) for the treatment of patients with BRAF V600 mutation-positive advanced melanoma.
The Food and Drug Administration (FDA) has approved a label change for Isentress (raltegravir; Merck) to include updated information about concomitant raltegravir and aluminium and/or magnesium-containing antacids.
Scientists at The Scripps Research Institute and other institutions have announced results from a new study on a novel drug candidate that has blocked every strain of HIV-1, HIV-2, and simian immunodeficiency virus (SIV) that has been isolated from humans or rhesus macaques.
Women with no history of depression who deliver a stillbirth may have an increased risk for long-lasting depression, according to research.
Recent findings from a series of studies have shown that tobacco packaging without labels or branding may deter new smokers and prevent habitual smokers from regular use.
Researchers have identified differences in protein biomarkers present in saliva that are associated with autism spectrum disorder (ASD), which may lead to a saliva-based test to aid in diagnosis.
The American College of Cardiology (ACC) and the American Heart Association (AHA) have started to work on a new guideline for the management of hypertension.
Lupin announced the launch of the InspiraChamber Anti-Static Valved Holding Chamber (VHC) to enhance delivery of aerosol therapy in the treatment of asthma.
Seattle Genetics has submitted a supplemental Biologics License Application (BLA) to the Food and Drug Administration (FDA) for Adcetris (brentuximab vedotin) as consolidation therapy immediately following an autologous stem cell transplant (ASCT) in Hodgkin lymphoma patients at high risk of relapse.
Celgene announced that the Food and Drug Administration (FDA) has expanded the use of Revlimid (lenalidomide) to include patients newly diagnosed with multiple myeloma, in combination with dexamethasone.
The Food and Drug Administration (FDA) has granted Orphan Drug designation to entrectinib (Ignyta) for the treatment of TrkA-positive, TrkB-positive, TrkC-positive, ROS1-positive or ALK-positive colorectal cancer.
Sprout Pharmaceuticals has resubmitted its New Drug Application (NDA) to the FDA for flibanserin for Hypoactive Sexual Desire Disorder (HSDD) in premenopausal women.
Orexo announced its plans to launch Zubsolv (buprenorphine and naloxone) sublingual tablets in a new 8.6mg/2.1mg strength.
The Food and Drug Administration (FDA) has granted Orphan Drug designation to Saposin C, the active ingredient in BXQ-350 (Bexion) for the potential treatment of glioblastoma multiforme.
Galderma announced the availability of Soolantra (ivermectin) Cream for the the treatment of rosacea.
The Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) for ALO-02 (oxycodone HCl and naltrexone HCl; Pfizer) extended-release capsules for the management of pain severe enough to require daily, around-the-clock, long term opioid treatment and for which alternative treatment options are inadequate.
The Food and Drug Administration (FDA) has granted Priority Review to the New Drug Application (NDA) for LCZ696 (Novartis) for the treatment of heart failure with reduced ejection fraction (HFrEF).
Lightlake Therapeutics and Adapt Pharma Limited announced that the Food and Drug Administration (FDA) has granted Fast Track designation to its intranasal naloxone, an opioid antagonist for opioid overdose reversal treatment.
Eisai announced that the Food and Drug Administration (FDA) has approved a supplemental New Drug Application (sNDA) for Banzel (rufinamide) as adjunctive treatment of seizures associated with Lennox-Gastaut Syndrome (LGS) in pediatric patients aged 1-4 years old.
The Food and Drug Administration (FDA) has approved Lenvima (lenvatinib; Eisai) for the treatment of patients with progressive, differentiated thyroid cancer whose disease progressed despite receiving radioactive iodine therapy.
The Food and Drug Administration (FDA) has approved Pazeo (olopatadine HCl ophthalmic solution; Alcon) for the treatment of ocular itching associated with allergic conjunctivitis.
The Food and Drug Administration (FDA) has granted clearance for the Cepheid Xpert MTB/RIF Assay to help determine if patients with suspected tuberculosis (TB) can be removed from airborne infection isolation with one or two negative test results.
The Food and Drug Administration (FDA) has granted marketing of Pelvalon's Eclipse System for the treatment of fecal incontinence in females aged 18-75 years old who have had more than four episodes in a two-week period.
Oral lenvatinib delayed progression of advanced thyroid cancer by 18 months, compared with four months for patients treated with a placebo, according to results from a new clinical trial.
Noven announced the launch of Minivelle (estradiol transdermal system) 0.025mg/day, a new low dosage strength approved for the prevention of postmenopausal osteoporosis.
New research published in The Journal of Pediatrics suggests that a plant-based, low-fat vegan diet can significantly reduce risk factors for cardiovascular disease in obese children.
Genzyme announced results from its extension study of the Phase 3 ENGAGE and ENCORE studies of Cerdelga (eliglustat) for the treatment of certain adults with Gaucher disease type 1.
The Food and Drug Administration (FDA) has granted Orphan Drug designation to VS-5584 (Verastem) for the treatment of mesothelioma.
The Food and Drug Administration (FDA) has granted Orphan Drug designation to its antinuclear antibody (ANA) conjugated liposomal doxorubicin (NanoSmart Pharmaceuticals) intended to treat Ewing's sarcoma, with potential expansion to other indications.
- Recall of Two IV Antibiotics Announced
- Five Things ID Experts Want You to Know Before You Prescribe an Antibiotic
- What's Changed in Immunization Recommendations From CDC Advisory Committee
- FDA: Testosterone Replacement Tx Review Prompts New Warnings, Updated Labeling
- IUD Approval Gives Women New Long-Acting Birth Control Option
- Can a Common Allergy Med Help Treat Lyme Disease?
- Afrezza Launch Gives Patients the Option of Insulin Without Injection
- Recommendations for Managing Hyperglycemia in T2DM: What's New for 2015
- FDA: Testosterone Replacement Tx Review Prompts New Warnings, Updated Labeling
- Peanut Allergy Patch Shows Promise in Latest Study
- HCTZ vs. Indapamide and Chlorthalidone: Head-to-Head Trials Reviewed
- Nanodevice With Dual Therapy May Help Fight Cancer Drug Resistance
- Sleep "Debt" Seen in Adults with Stress, Poor Health
- MDs See Reduced Opioid Rx With State Drug Monitoring Programs
- FDA: Testosterone Replacement Tx Review Prompts New Warnings, Updated Labeling